United States was Caribou Biosciences’s largest region in fiscal 2025, bringing in $9.48M of $11.16M (85%).
| Geography | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| United States | $13.30M | $32.77M | $9.27M | $9.48M | |||
| Rest Of World | $548.00K | $1.71M | $724.00K | $1.68M | |||
| Total | $13.85M | $34.48M | $9.99M | $11.16M |
Caribou Biosciences brought in $11.16M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 11.7% from $9.99M in fiscal 2024. United States was the largest at $9.48M (84.9%), ahead of Rest Of World at $1.68M (15.1%).
Compared with fiscal 2024, Rest Of World grew 132.2% to $1.68M and United States grew 2.2% to $9.48M. From fiscal 2022 to 2025, combined revenue from these regions fell from $13.85M to $11.16M, a compound annual decline of 7.0%. United States' share of the total fell from 96.0% to 84.9%.
Point In Time was Caribou Biosciences’s largest revenue line in fiscal 2025, bringing in $8.70M of $11.20M (78%).
| Timing of Transfer of Good or Service | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Over Time | $8.00M | $26.10M | $2.50M | $2.50M |
| Point In Time | $5.90M | $8.40M | $7.50M | $8.70M |
| Total | $13.90M | $34.50M | $10.00M | $11.20M |
Caribou Biosciences brought in $11.20M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 12.0% from $10.00M in fiscal 2024. Point In Time was the largest at $8.70M (77.7%), ahead of Over Time at $2.50M (22.3%).
Compared with fiscal 2024, Point In Time grew 16.0% to $8.70M and Over Time grew 0.0% to $2.50M. From fiscal 2022 to 2025, combined revenue from these revenue lines fell from $13.90M to $11.20M, a compound annual decline of 6.9%. Point In Time's share of the total rose from 42.4% to 77.7%.
Caribou Biosciences (CRBU) reports its revenue by geography and by timing of transfer of good or service. In fiscal 2025, United States was its largest region, bringing in $9.48M (84.9% of the total), followed by Rest Of World at $1.68M (15.1%).
United States was Caribou Biosciences' largest region in fiscal 2025, bringing in $9.48M, or 84.9% of the $11.16M total across its two regions.
Point In Time was Caribou Biosciences' largest revenue line in fiscal 2025, bringing in $8.70M, or 77.7% of the $11.20M total across its two revenue lines.
Rest Of World grew faster than United States in fiscal 2025, up 132.2% from $724.00K to $1.68M. United States grew 2.2% to $9.48M.
Every figure comes from Caribou Biosciences' annual financial filings, as reported. Each line keeps the name Caribou Biosciences gives it, and years follow its fiscal calendar.
Caribou Biosciences' revenue by geography goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.